FDA.reportPublic FDA data

halobetasol propionate 0.01 % / tazarotene 0.045 % Topical Lotion

RxCUI
2166089
RxNorm name
halobetasol propionate 0.01 % / tazarotene 0.045 % Topical Lotion
Display name
halobetasol propionate 0.01 % / tazarotene 0.045 % Topical Lotion
Full name
halobetasol propionate 0.01 % / tazarotene 0.045 % Topical Lotion
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:17

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
DuobriiHALOBETASOL PROPIONATE AND TAZAROTENEBausch Health US, LLCb3f0cdc0-69fd-43d1-baf2-d776a3a207152020-01-01Warnings, Adverse reactionsExact identifier
rxcui: 2166089

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
b3f0cdc0-69fd-43d1-baf2-d776a3a20715halobetasol propionate 0.01 % / tazarotene 0.045 % Topical LotionPSN6These highlights do not include all the information needed to use DUOBRII safely and effectively. See full prescribing information for DUOBRII. DUOBRII ® (halobetasol propionate and tazarotene) lotion, for topical use Initial U.S. Approval: 201920200101
b3f0cdc0-69fd-43d1-baf2-d776a3a20715halobetasol propionate 0.1 MG/ML / tazarotene 0.45 MG/ML Topical LotionSCD6These highlights do not include all the information needed to use DUOBRII safely and effectively. See full prescribing information for DUOBRII. DUOBRII ® (halobetasol propionate and tazarotene) lotion, for topical use Initial U.S. Approval: 201920200101
b3f0cdc0-69fd-43d1-baf2-d776a3a20715halobetasol propionate 0.01 % / tazarotene 0.045 % Topical LotionSY6These highlights do not include all the information needed to use DUOBRII safely and effectively. See full prescribing information for DUOBRII. DUOBRII ® (halobetasol propionate and tazarotene) lotion, for topical use Initial U.S. Approval: 201920200101